---
title: "Nasal curettes versus nasopharyngeal swabs for longitudinal nasal T-cell immunophenotyping"
id: "frontiers-in-immunology-12-comparative-evaluation-of-nasal-curettes-and-nasopharyngeal-swabs-for"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-comparative-evaluation-of-nasal-curettes-and-nasopharyngeal-swabs-for"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1985779"
published_at: "2026-11-16T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nasal curettes versus nasopharyngeal swabs for longitudinal nasal T-cell immunophenotyping
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-comparative-evaluation-of-nasal-curettes-and-nasopharyngeal-swabs-for
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1985779)
- **Published At:** 2026-11-16T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source page did not include the study abstract, numerical results, or cohort characteristics; investigators and institutions were not listed on the provided content. - No methodology details were available on the source page: the sample size, sampling schedule, specific assays used for **T-cell** phenotyping, gating strategies, or statistical tests were not reported. - The source did not provide primary or secondary endpoints, so clinical endpoints such as reproducibility, cell yield, marker stability over time, or tolerability were absent. - There were no results reported comparing **nasal curettes** and **nasopharyngeal swabs** for lymphocyte yield, viability, or surface-marker expression. - Safety and tolerability data (adverse events, discomfort scores) were not present on the captured page. - The page lacked discussion points, limitations, or stated next steps from the authors; no regulatory or translational implications were provided. - For readers and clinicians, the missing items needed to interpret the work include population demographics, longitudinal follow-up intervals, assay panels, and any correlations with clinical or virologic measures. - The document available was primarily Frontiers site navigation and header material rather than the article body; the actual research text was not accessible via the provided content.
## Clinical Analysis & Structured Key Points
Frontiers | Comparative evaluation of nasal curettes and nasopharyngeal swabs for longitudinal human nasal T-cell immunophenotyping 1 year, underwent weekly paired nasal curette and nasopharyngeal swab sampling for 5 weeks. Conventional and innate-like T-cell populations were quantified by flow cytometry to assess T-cell composition, HIV-associated perturbations, longitudinal stability, and measurement reproducibility.ResultsNasopharyngeal swabs yielded greater immune cell enrichment than nasal curettes, yet recovered nasal T-cell profiles were broadly comparable. Conventional CD4+ and CD8+ T-cell proportions differed modestly between sampling methods, whereas innate-like T-cell populations and CCR6/CXCR3-defined T-cell phenotypes were broadly conserved. Nasal curettes more readily detected HIV-associated perturbations in conventional and CXCR3+ CD4+ T-cell populations than nasopharyngeal swabs. Nasal T-cell composition remained stable over 5 weeks. In contrast, repeated sampling elicited dynamic CXCR3-associated T-cell phenotypic responses in HIV-uninfected adults and PWH on long-term ART that were absent during early ART. Finally, nasal curettes demonstrated lower within-participant variability and greater reproducibility during longitudinal sampling than nasopharyngeal swabs.ConclusionsNasal curettes and nasopharyngeal swabs recover generally comparable human nasal T-cell profiles. However, the greater sensitivity of nasal curettes for detecting immune perturbations and their improved reproducibility over time may offer advantages for longitudinal nasal T-cell immunophenotyping studies."> ORIGINAL RESEARCH article Front. Immunol. , 16 November 2026 Sec. Mucosal Immunity Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1985779 Published in Frontiers in Immunology Mucosal Immunity 7 impact factor 11.3 citescore Editor & Reviewers Edited by T B Tanima Bose Reviewed by A S Aloysious Ssemaganda J G Jason Girkin Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Figure 4 View in article Table 1 Participant demographic characteristics by HIV status. View in article ORIGINAL RESEARCH article Front. Immunol. , 16 November 2026 Sec. Mucosal Immunity Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1985779 Comparative evaluation of nasal curettes and nasopharyngeal swabs for longitudinal human nasal T-cell immunophenotyping J A Joseph A. Phiri 1 * G K Gloria Kapira 1,2 R K Robert K. Nyirenda 1 E L Edwin Lisimba 1 N M Ndaona Mitole 1 A K Alice Kusakala 1 P C Precious Chigamba 1 C K Chisomo Kafamau 1 A D Austin D. Kumwenda 1 L M Lukerensia Mlongoti 1,2 J Z Janet Zambezi 1 M N Memory N. Mvula 1 A P Aaron P. Chirambo 1 N J Ndaru Jambo 1 L L Lusako L. Sibale 1 +7 more K C Kondwani C. Jambo 1,2,3 * 1. Infection and Immunity Research Group, Malawi-Liverpool-Wellcome Research Programme, Blantyre, Malawi 2. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place Liverpool, United Kingdom 3. Department of Medical Laboratory Sciences, Kamuzu University of Health Sciences, Blantyre, Malawi See more Article metrics View details Abstract Background: The upper respiratory tract is a key entry point for respiratory pathogens, making it a critical niche that shapes infection outcomes. Longitudinal immunophenotyping of the human nasal mucosa is increasingly used to investigate respiratory mucosal immunity, yet the optimal sampling method for longitudinal studies remains unclear, particularly in high-transmission settings. Methods: Seventy-six asymptomatic adults, comprising HIV-uninfected individuals, people with HIV (PWH) receiving antiretroviral therapy (ART) for 1 year, underwent weekly paired nasal curette and nasopharyngeal swab sampling for 5 weeks. Conventional and innate-like T-cell populations were quantified by flow cytometry to assess T-cell composition, HIV-associated perturbations, longitudinal stability, and measurement reproducibility. Results: Nasopharyngeal swabs yielded greater immune cell enrichment than nasal curettes, yet recovered nasal T-cell profiles were broadly comparable. Conventional CD4 + and CD8 + T-cell proportions differed modestly between sampling methods, whereas innate-like T-cell populations and CCR6/CXCR3-defined T-cell phenotypes were broadly conserved. Nasal curettes more readily detected HIV-associated perturbations in conventional and CXCR3 + CD4 + T-cell populations than nasopharyngeal swabs. Nasal T-cell composition remained stable over 5 weeks. In contrast, repeated sampling elicited dynamic CXCR3-associated T-cell phenotypic responses in HIV-uninfected adults and PWH on long-term ART that were absent during early ART. Finally, nasal curettes demonstrated lower within-participant variability and greater reproducibility during longitudinal sampling than nasopharyngeal swabs. Conclusions: Nasal curettes and nasopharyngeal swabs recover generally comparable human nasal T-cell profiles. However, the greater sensitivity of nasal curettes for detecting immune perturbations and their improved reproducibility over time may offer advantages for longitudinal nasal T-cell immunophenotyping studies. Introduction The upper respiratory tract (URT) is a major portal of entry for respiratory pathogens and a key site for initiating mucosal immune responses ( 1 , 2 ). Immune populations within the nasal mucosa contribute to defence against invading microorganisms, making this compartment particularly relevant for understanding immunity to respiratory infection and mucosal vaccination ( 1 , 2 ). However, much of our understanding of human cellular immunity has historically been derived from peripheral blood, despite growing recognition that immune cell composition and function differ substantially across anatomical compartments ( 3 , 4 ). Direct and longitudinal assessment of the nasal immune compartment is therefore important for defining the dynamics of human respiratory mucosal immunity. Several minimally invasive approaches are available for sampling the human nasal mucosa, including nasal washes, nasosorption, nasopharyngeal swabs, and nasal curettage ( 5 – 7 ). Nasopharyngeal swabs and nasal curettage are minimally invasive approaches that recover both epithelial and immune cells from the nasal mucosa and are increasingly used for cellular immunological studies ( 6 , 8 – 11 ). However, whether these approaches recover comparable T-cell populations or differ in their ability to detect biologically relevant immune perturbations remains poorly defined. Furthermore, despite the increasing use of repeated nasal sampling in longitudinal studies ( 6 , 8 – 11 ), both the temporal stability of nasal T-cell populations and the reproducibility of measurements obtained using different sampling approaches remain incompletely understood. Evaluating sampling approaches also requires a biological context in which differences in T-cell composition can be expected. HIV infection provides such a context, with well-characterised alterations in T-cell composition across systemic and mucosal compartments and antiretroviral therapy (ART)-associated restoration of several T-cell abnormalities ( 12 – 14 ). Inclusion of HIV-uninfected adults and people with HIV (PWH) receiving early or long-term ART therefore provides a biological contrast for evaluating the ability of different sampling approaches to detect biologically relevant differences in T-cell composition. Here, we compared paired nasopharyngeal swabs and nasal curettes collected weekly over 5 weeks from HIV-uninfected adults and PWH on short- or long-term ART. We compared the T-cell populations recovered by each approach and their detection of HIV-associated immune perturbations, while assessing the temporal stability of nasal T-cell composition and reproducibility of longitudinal measurements. Methods Ethics statement This study was conducted in accordance with local and international ethical regulations and the Declaration of Helsinki. Ethical approval was granted by the National Health Science Research Committee (Protocol #21/24/2680, Malawi) and the Liverpool School of Tropical Medicine Research Ethics Committee (Protocol #21-035, Liverpool, United Kingdom). All participants recruited into the study provided written informed consent prior to enrolment. Study design The study was a longitudinal observational cohort design, conducted between September 2021 and December 2023, and aimed to assess URT mucosal responses following repeated sampling in PWH at different stages of ART. Asymptomatic healthy adults aged 18–45 years were recruited from the Queen Elizabeth Central Hospital Lighthouse HIV Clinic and Blantyre District Office Gateway Clinic in Blantyre, Malawi. Participants were stratified into three groups consisting of ( 1 ) HIV-uninfected adults ( 2 ), PWH on ART for 1 year. HIV status for PWH was self-reported and confirmed in the health passport book (a personal health record). For HIV-uninfected individuals, HIV status was confirmed using a standard HIV rapid test protocol involving two independent rapid tests. ART duration and regimen were confirmed using official clinical records, and ART adherence was confirmed via official clinical pharmacy refill records. In addition, HIV viral control was confirmed using plasma viral load testing. Exclusion criteria included any signs or symptoms of acute illness, chronic medical conditions, active SARS-CoV-2 infection using polymerase chain reaction (PCR), or self-reported SARS-CoV-2 infection within the preceding 14 days. Participants were screened in accordance with local clinical protocols. Nasal sample collection We collected paired nasal cells from the URT by gently scraping the nasal inferior turbinate using nasal curettes (Rhino-Pro, Arlington Scientific) and collected cells using a nasopharyngeal swab (Floq swab). One curette and nasopharyngeal swab per nostril was transferred into cold RPMI 1640 medium supplemented with 10% fetal bovine serum (Sigma-Aldrich), 1% HEPES (Thermo Fisher Scientific), and 1% penicillin and streptomycin (Thermo Fisher Scientific); transported on ice; and processed within 30 min. All samples with visible blood contamination were excluded from the analysis. For flow cytometry analysis, cells were dislodged by pipetting liquid up and down the tip of the curette or the nasopharyngeal swab, then centrifuged at 500 g for 10 min at 4°C. The supernatant was completely removed, and cells were resuspended in 500 µL of PBS (Thermo Fisher Scientific). Flow cytometry and immunophenotyping Nasal cells were dislodged from the nasal curette and the nasopharyngeal swab. The dislodged cells were centrifuged at 500 g for 5 min, resuspended in phosphate-buffered saline (PBS) and stained with pre-diluted (1:500) Far-red amine reactive dye for viability analysis (Thermo Fisher Scientific). Cells were then incubated for 5 min, washed at 500 g for 5 min, and stained with a panel of antibodies including Brilliant Violet 605™ anti-human CD326 (EpCAM), APC-Cy7 anti human CD3 antibody, PerCP-Cy5.5 anti-human CD4, Alexa Fluor 700 ® anti-human CD8, PE anti-human TCRVα7.2 antibody, PE-Texas Red anti-human CD161, FITC anti-human TCRγδ, APC anti-human CD56, Brilliant Violet 421™ anti-human CCR6, and Brilliant Violet 605™ anti-human CXCR3. Single-stained bead-based compensation controls were included in the analysis. Nasal cells and compensation controls were acquired using a BD LSRFORTESSA™ cytometer (BD Biosciences). A minimum of 50,000 total events were acquired per sample, and FlowJo v10.1 (BD Biosciences) was used for analysis. Statistical analysis All statistical analyses were performed in R version 4.6.0. For each phenotype, a linear mixed-effects model was fitted to the proportion on its original percentage scale. Visit, HIV status, sampling method, and all interactions were included as fixed effects. Participant random intercept accounted for repeated measurements across visits, while the laboratory-identifier random intercept accounted for correlation between sampling method measurements obtained from the same sample set. Models were fitted using restricted maximum likelihood. When the participant random-effect variance was singular, the model was refitted with the laboratory-identifier random intercept alone. Estimated marginal means and corresponding 95% confidence intervals were calculated for every combination of phenotype, visit, HIV status, and sampling method. All statistical comparisons between groups were performed using a two-sided non-parametric Wilcoxon test or Kruskal–Wallis test with a multiple testing Benjamini–Hochberg false discovery rate (BH FDR) applied where appropriate. Effect sizes were calculated using Cliff’s Delta test with reported lower and upper confidence intervals. Sample sizes are detailed in a figure legend. Results Participant characteristics and sampling We recruited 76 asymptomatic healthy adults between the ages of 18 and 45 years from the Queen Elizabeth Central Hospital Lighthouse ART Clinic and the Gateway Voluntary Counselling and Testing Centre in Blantyre, Malawi. Participants comprised 23 HIV-uninfected adults, 30 PWH within 3 months of ART initiation (PWH on ART for 1 year). Participants were followed up weekly for 5 weeks, with paired nasal cell samples collected from the inferior turbinate (using a nasal curette) and the nasopharynx (using a nasopharyngeal swab) at each visit ( Figure 1A ). We also collected peripheral blood samples at baseline for absolute CD4 count and HIV viral load testing. We compared participant characteristics, such as age, sex distribution, CD4 count, HIV viral load, and ART duration ( Table 1 ). Age and sex were distributed similarly across the groups. Among PWH, the median ART duration was 1 month [interquartile range (IQR); 0,1] for PWH on ART for 1 year. Median peripheral absolute CD4 counts were 886 cells/μL (IQR; 758, 1,018.5), 469 cells/μL (IQR; 269.5, 669.8), and 595 cells/μL (IQR; 477.5, 779.5) for HIV-uninfected adults, PWH on ART for 1 year, respectively. Detectable plasma HIV viral load was only observed in 37% (11/30) of PWH on ART for 1 year had undetectable plasma viral load. Figure 1 Nasopharyngeal swabs and nasal curettes recover comparable nasal T-cell profiles. Nasal cells collected from the nasopharynx using a nasopharyngeal swab and the inferior turbinate using a nasal curette were stained with fluorochrome-conjugated antibodies to identify T-cell and their phenotypes. (A) Study design showing the recruitment and follow-up of participants in this study. (B) Paired boxplot showing the leukocyte epithelial cell ratio in the nasal curette and nasopharyngeal swabs of HIV-uninfected adults. (C) PCA showing the overall similarity of nasal T cells from the nasal curette or the nasopharyngeal swab. (D) Boxplot showing the proportion of conventional CD4 + T cells and CD8 + T cells. (E) Proportion of innate-like T cells including CD3 + TCRvα7.2 + T cells, CD3 + γδ + T cells, and CD3 + CD56 + T cells. (F, G) Proportion of CCR6 and/or CXCR3 within (F) CD4 + T cells and (G) CD8 + T cells. Connecting lines show paired samples in the nasal curette and the nasopharyngeal swab. Boxplots show the median and 75th and 25th percentile. Statistical analysis was done using a paired Wilcoxon test in R with p -value 1 year ( N = 23) p -value Age, years 37 (31, 40.5) 33 (29, 37) 36 (32, 38.5) 0.139 Sex 0.339 Female 13 (56.5%) 11 (36.7%) 12 (52.2%) Male 10 (43.5%) 19 (63.3%) 11 (47.8%) HIV viral load 0.001 Not detected — 18 (62.1%) 22 (100.0%) Detected — 11 (37.9%) 0 (0.0%) Absolute CD4 count, cells/µL 886 (758, 1,018.5) 469 (269.5, 669.8) 595 (477.5, 779.5) 1 year ( p = 0.04), whereas the proportion of CD8 + T cells was higher, with a trend towards statistical significance ( p = 0.0610) ( Figures 2A–C ). Flow cytometry event counts corroborated this decrease in CD4 + T-cell counts in nasal curettes of PWH on ART for 1 year ( p = 0.0100) compared with HIV-uninfected ( Supplementary Figure S2A ). In contrast, the proportion of CD4 + T cells was lower in nasopharyngeal swabs from PWH on ART for <3 months than in HIV-uninfected adults,
## Related Clinical Research

- [Innate immune states linked to different serological responses after syphilis treatment](https://medichelpline.com/clinical-feed/biorxiv-3-distinct-innate-immune-states-associate-with-divergent-serological-outcomes.md)
- [Methamphetamine reshapes immune cell and plasma signatures in people with HIV](https://medichelpline.com/clinical-feed/medrxiv-14-methamphetamine-use-reshapes-cellular-and-plasma-immune-signatures-in-a-lineage.md)
- [EmERGE mHealth for HIV care: sustained patient activation and safety over 3.2 years](https://medichelpline.com/clinical-feed/pubmed-43059328.md) (DOI: 10.1080/25787489.2026.2759372)
- [New Zealand progress toward eliminating HIV by 2030: trends, gaps, and priorities](https://medichelpline.com/clinical-feed/pubmed-43056630.md) (DOI: 10.26635/6965.7595)
- [Impact of loss to follow-up on 5-year mortality after tuberculosis treatment in São Paulo, Brazil](https://medichelpline.com/clinical-feed/plos-medicine-0-loss-to-follow-up-during-tuberculosis-treatment-and-5-year-mortality-in-brazil.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.